Skip to main content
Log in

Bone density assessment in a cohort of pediatric patients affected by 22q11DS

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Objective

Hypoparathyroidism and hypocalcemia are two of the most frequent clinical characteristics of 22q11-deletion syndrome (22q11DS). The aim of this study was to evaluate bone metabolism and density in a cohort of patients affected by 22q11DS.

Methods

In 8 pediatric patients (mean age 11.5 years; range 7–16.4) affected by 22q11DS, creatinine, albumin, total and ionized calcium, phosphate, 25(OH) vitamin D, parathyroid hormone, osteocalcin, C-terminal telopeptide and interleukin 6 were assessed. Furthermore, bone mineral density (BMD) was determined by dual-energy X-ray absorptiometry procedure. 14 healthy children were considered as controls.

Results

Most of the studied subjects were overweight and lacked quality physical activity. 40 % of the subjects had reduced calcium levels in the absence of related clinical symptoms and all patients also had inadequate levels of Vitamin D. The values of L1-L4 BMD were within the reference range in all patients (z score <2). However, after comparing the age-matched indexes of bone mineralization of patients with those of controls, the former had lower bone mineralization indexes than the latter.

Conclusions

In pediatric patients with 22q11DS, an initial and slight bone loss is evident. The incidence of hypocalcemia is underestimated because hypocalcemia is asymptomatic. Several factors contribute to bone impairment in children who still have to achieve bone mass peak. Therefore, we suggest strict monitoring of bone metabolism as well as BMD measurement in patients affected by 22q11DS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

22q11DS:

22q11-Deletion syndrome

BMD:

Bone mineral density

BMI:

Body mass index

PTH:

Parathyroid hormone

CTX:

C-terminal telopeptide of type I collagen

IL-6:

Interleukin 6

BMC:

Bone mineral content

DXA:

Dual-energy X-ray absorptiometry

aBMD:

Areal BMD

References

  1. Scambler PJ (2000) The 22q11 deletion syndromes. Hum Mol Genet 9:2421–2426

    Article  CAS  PubMed  Google Scholar 

  2. Oskarsdottir S, Vujic M, Fast A (2004) Incidence and prevalence of the 22q11 delection syndrome: a population-based study in Western Sweden. Arch Dis Child 89:148–151

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Bonnet D (2006) Epidemiology and genetics of congenital heart diseases and cardiomyopathies in children. Rev Prat 56:599–604

    PubMed  Google Scholar 

  4. Robin N, Shprintzen R (2005) Defining the clinical spectrum of delection 22q11.2. J Pediatr 147:90–96

    Article  PubMed  Google Scholar 

  5. Brauner R, Harivel Le, de Gonneville A (2003) Parathyroid function and growth in 22q11.2 deletion syndrome. J Pediatr 142:504–508

    Article  CAS  PubMed  Google Scholar 

  6. Ruiz JC, Mandel C, Garabedian M (1995) Influence of spontaneous calcium intake and physical exercise on the vertebral and femoral bone mineral density of children and adolescents. J Bone Miner Res 10:675–682

    Article  CAS  PubMed  Google Scholar 

  7. Schoenau E, Land C, Stabrey A, Remer T, Kroke A (2004) The bone mass concept: problems in short stature. Eur J Endocrinol 151(Suppl 1):S87–S91

    Article  CAS  PubMed  Google Scholar 

  8. Stagi S, Lapi E, Gambineri E, Manoni C, Genuardi M, Colarusso G, Conti C, Chiarelli F, de Martino M, Azzari C (2010) Bone density and metabolism in subjects with microdeletion of chromosome 22q11. Eur J Endocrinol 163:329–337

    Article  CAS  PubMed  Google Scholar 

  9. Bassett AS, McDonald-McGinn DM, Devriendt K, Digilio MC, Goldenberg P, V A, Marino B, Oskarsdottir S, Philip N, Sullivan K, Swillen A, Vorstman J, International 22q11.2 Deletion Syndrome Consortium (2011) Pratical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 159:332–339

    Article  PubMed Central  PubMed  Google Scholar 

  10. Nguyen TV, Maynard LM, Towne B, Roche AF, Wisemandle W, Li J, Guo SS, Chumlea WC, Siervogel RM (2001) Sex differences in bone mass acquisition during growth. J Clin Densitom 4:147–157

    Article  CAS  PubMed  Google Scholar 

  11. Weinzimer SA (2001) Endocrine aspects of 22q11.2 deletion syndrome. Genet Med 3:19–22

    Article  CAS  PubMed  Google Scholar 

  12. Cuneo BF, Driscoll DA, Gidding SS, Langman CB (1997) Evolution of latent hypoparathyroidism in familial 22q11 deletion syndrome. Am J Med Genet 69:50–55

    Article  CAS  PubMed  Google Scholar 

  13. Karlsson MK, Linden C, Karlsson C, Johnell O, Obrant K, Seeman E (2000) Exercise during growth and bone mineral density and fractures in old age. Lancet 355:469–470

    Article  CAS  PubMed  Google Scholar 

  14. Karlsson KM, Karlsson C, Ahlborg HG, Valdimarsson O, Ljunghall S, Obrant KJ (2003) Bone turnover responses to changed phisycal activity. Calcif Tissue Int 72:675–680

    Article  CAS  PubMed  Google Scholar 

  15. Peruzzi B, Cappariello A, Del Fattore A, Rucci N, De Benedetti F, Teti A (2012) c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling. Nat Commun 3:630

    Article  PubMed  Google Scholar 

  16. Bachrach LK (2001) Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 12:22–28

    Article  CAS  PubMed  Google Scholar 

  17. Mora S, Gilsanz V (2003) Establishment of peak bone mass. Endocrinol Metab Clin North Am 32:39–63

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest. No external funding, apart from the support of the Polytechnic University of Marche, was available for this study.

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the parents of participants included in the study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to G. Balercia.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ficcadenti, A., Zallocco, F., Neri, R. et al. Bone density assessment in a cohort of pediatric patients affected by 22q11DS. J Endocrinol Invest 38, 1093–1098 (2015). https://doi.org/10.1007/s40618-015-0295-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-015-0295-6

Keywords

Navigation